Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: elias on November 19, 2016, 04:48:23 pm
-
]]http://liverlearning.aasld.org/aasld/2015/thelivermeeting/110677/[[$item.link]] (http://liverlearning.aasld.org/aasld/2015/thelivermeeting/110677/[[$item.link)
At the lowest planned dose 6 out of 8 subjects had at least 1 stage reduction in Ishak score (mean reduction 1.25, range 0-4, N=8), and 1 subject showed reduction of METAVIR score from F-3 to F-0 right after 5 weeks dosing. Conclusion: ND-L02-s0201 was well tolerated in both studies with no dose limiting toxicities up to 0.8 mg/kg (single) and of 0.2 mg/kg/week (multiple doses). The PK results were consistent between healthy subjects and patients as well as for single and multiple doses with no drug accumulation. Histologic improvement was seen in the majority of patients at the lowest dose studied.
A few days ago, November 10, 2016 Bristol-Myers Squibb purchased rights to development of Denko's anti-fibrosis investigational drug:
https://hepatitiscnewdrugs.blogspot.com/2016/11/bristol-myers-squibb-signs-exclusive.html (https://hepatitiscnewdrugs.blogspot.com/2016/11/bristol-myers-squibb-signs-exclusive.html)
Nitto Denko's studies are for advanced fibrosis due to either NASH or HCV
-
Wow! Excellent news thanks!
-
Hi Lynn:
Ive seen reports about other treatment being studied as well. This was only one I had saved so far.
There will be many now who have cleared HCV. So increasing demand for improving fibrosis. Some developments along those lines for NASH might be applicable for those cured of HCV
-
Even so with the present state of my liver I seem to be limping along ok with my lumpy bumpy rock hard liver so far so as long as I don't get HCC I think I am ok now but yeah getting rid of ascities and edema, killer leg cramps probably from the duretic I take, and having my platelet count rise to normal range would be awesome too.